

**PedSAP 2020 Book 1 (*Gastroenterology and Hepatology*)**

**Release date: March 16, 2020**

**BCPPS test deadline:** 11:59 p.m. (Central) on September 15, 2020.

**ACPE test deadline:** 11:59 p.m. (Central) on March 14, 2023.

**ISBN-13:** 978-1-932658-32-3



**Continuing Pharmacy Education Credit:** The American College of Clinical Pharmacy

is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE).

**PedSAP Target Audience:** The target audience for PedSAP 2020 Book 1 (*Gastroenterology and Hepatology*) is board-certified and advanced-level critical care pharmacists caring for pediatric patients with gastroenterologic and hepatologic disorders

**Module I (4.0 CPE): UAN 0217-0000-20-010-H01-P**

**Chapter: Nausea/Vomiting, Cyclic Vomiting Syndrome, and Cannabinoid Hyperemesis Syndrome**

**Learning Objectives**

1. Evaluate nausea, vomiting, and other supporting symptoms to differentiate acute, chronic, and cyclic causes of vomiting.
2. Design appropriate treatment of nausea/vomiting based on the underlying etiology.
3. Develop a treatment plan for cyclic vomiting syndrome to include abortive and prophylactic therapy when indicated.
4. Evaluate treatment options for cannabinoid hyperemesis syndrome in the pediatric population.

**Chapter: Constipation**

**Learning Objectives**

1. Apply knowledge of the functional causes and development of constipation in pediatric patients.
2. Develop a treatment plan using nonpharmacologic and pharmacologic options for pediatric patients who have functional constipation.
3. Evaluate the medications used for treatment and the role of therapy in special pediatric populations with constipation.
4. Design strategies for management of long-term complications of constipation.

**Module II (5.5 CPE): UAN 0217-0000-20-011-H01-P**

**Chapter: IBD: Novel Therapy and Biosimilars**

**Learning Objectives**

1. Distinguish clinical scenarios when biosimilar therapies are appropriate and design pharmacotherapy regimens for pediatric inflammatory bowel disease (IBD) using biosimilar agents.
2. Compare and contrast the approval process, immunogenicity, and clinical utility of biologic agents with biosimilar agents in the treatment of pediatric IBD.
3. Evaluate the use of biosimilar agents in pediatric patients with IBD.

### **Chapter: Pancreatitis and Appendicitis**

#### **Learning Objectives**

1. Distinguish among various bacterial organisms isolated in patients with uncomplicated or complicated appendicitis.
2. Devise a postoperative plan that incorporates intravenous fluids and pain management strategies.
3. Develop an intravenous antibiotic plan for a pediatric patient with complicated appendicitis using current published guidelines.
4. Analyze the differences in the etiology and clinical presentation of acute pancreatitis in pediatric patients.
5. Devise a fluid resuscitation regimen for a patient with acute pancreatitis and nutrition plan based on nutrition status and severity of pancreatitis.
6. Evaluate criteria for when antibiotic therapy is appropriate for acute pancreatitis.

### **Module III (5.5 CPE): UAN 0217-0000-20-012-H01-P**

### **Chapter: Intestinal Rehabilitation and Short Bowel Syndrome**

#### **Learning Objectives**

1. Assess for the impact of resection of a significant portion of the jejunum, ileum, and ileocecal valve on the absorption of nutrients.
2. Justify the role of enteral nutrition in intestinal adaptation.
3. Design a parenteral nutrition (PN) formulation and monitoring plan for a patient based on acuity and length of PN therapy.
4. Justify appropriate antidiarrheal therapy based on patient data.
5. Devise a strategy for minimizing the development of cholestasis and PN-associated liver disease in patients with short bowel disease.

### **Chapter: Acute and Chronic Liver Failure**

#### **Learning Objectives**

1. Design a treatment plan for the patient with acute liver failure based on presentation of symptoms and etiology of liver disease.
2. Distinguish between acute liver failure and chronic liver failure in children.
3. Design a treatment plan for the patient with chronic liver failure based on etiology of liver disease and presentation of symptoms.
4. Evaluate a drug regimen plan for chronic liver failure based on patient-specific factors.

### **Module IV (4.0 CPE): UAN 0217-0000-20-013-H01-P**

### **Feature: Recorded Webinar: Controversies in Stress Ulcer Prophylaxis**

#### **Learning Objectives**

1. Assess for the complications of GI bleeding in pediatric patients.
2. Evaluate indications for stress ulcer prophylaxis in the pediatric population.
3. Justify the use of an H2-antagonist versus a proton pump inhibitor for stress ulcer prophylaxis
4. Distinguish consequences associated with prolonged use of H2-antagonists and proton pump inhibitors.
5. Design a patient-specific stress ulcer prophylaxis regimen.

### **Feature: Interactive Case: Drug-induced Liver Injury**

#### **Learning Objectives**

1. Evaluate the drugs commonly associated with drug-induced liver injury (DILI).
2. Distinguish between the different mechanisms for DILI.
3. Devise a treatment plan for a patient presenting with acetaminophen toxicity.
4. Evaluate a patient case to determine the presence of DILI.

### **Feature: Interactive Case: Chronic Abdominal Pain Syndromes**

#### **Learning Objectives**

1. Distinguish risk factors for patients with eosinophilic esophagitis (EoE) and describe the incidence of EoE in the pediatric population.
2. Devise a treatment plan for patients with EoE.
3. Evaluate the signs and symptoms of functional abdominal pain and abdominal migraines.
4. Design a treatment plan for functional abdominal pain and abdominal migraines.